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The RNA polymerase II complex (pol II) is responsible for transcription of all21,000 human protein-encoding genes. Here, we describe
sixteen individuals harboring de novo heterozygous variants in POLR2A, encoding RPB1, the largest subunit of pol II. An iterative
approach combining structural evaluation andmass spectrometry analyses, the use of S. cerevisiae as a model system, and the assessment
of cell viability in HeLa cells allowed us to classify eleven variants as probably disease-causing and four variants as possibly disease-
causing. The significance of one variant remains unresolved. By quantification of phenotypic severity, we could distinguish mild and
severe phenotypic consequences of the disease-causing variants. Missense variants expected to exert only mild structural effects led
to amalfunctioning pol II enzyme, thereby inducing a dominant-negative effect on gene transcription. Intriguingly, individuals carrying
these variants presented with a severe phenotype dominated by profound infantile-onset hypotonia and developmental delay.
Conversely, individuals carrying variants expected to result in complete loss of function, thus reduced levels of functional pol II from
the normal allele, exhibited the mildest phenotypes. We conclude that subtle variants that are central in functionally important do-
mains of POLR2A cause a neurodevelopmental syndrome characterized by profound infantile-onset hypotonia and developmental delay
through a dominant-negative effect on pol-II-mediated transcription of DNA.
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Introduction
Human POLR2A (MIM: 180660) encodes the highly-
conserved RPB1 protein, which is the largest of twelve sub-
units of the essential RNA polymerase II (pol II) enzyme.1,2
This protein complex is responsible for the transcription of
all protein-encoding genes, as well as several long and
short non-coding RNA genes.3 Due to its central role in
gene expression, pol II and the regulation of its activity
have been studied in depth since its discovery fifty years
ago.4 Biochemical and structural studies have shown that
transcription initiation by pol II requires a set of basal (or
general) transcription factors. After assembly of the pol II
initiation complex at the promoter region, these factors
are exchanged for transcription elongation factors
including TFIIS, DSIF, and P-TEFb to allow processive
RNA synthesis by pol II.5 Detailed structural analysis of
the pol II of Saccharomyces cerevisiae (S. cerevisiae)6 revealed
different aspects of RNA synthesis, including initiation,7–10
nucleotide binding,11 chain elongation,12–16 error correc-
tion, and back tracking.17–20 For example, during the elon-
gation cycle, the incorporation of the incoming nucleotide
involves movement of the so-called RPB1 trigger loop,
which induces the forward movement of pol II over the
DNA template strand coincident with nucleotide selec-
tion. In vivo dynamics of pol II during initiation and
promotor pausing were studied in GFP-RPB1 knock-in
cells, and this research demonstrated that the continuous
release and reinitiation of promotor-bound pol II is impor-
tant for transcriptional regulation.21 Mutational studies
focusing on S. cerevisiae and human RPB1 indicated that
residues in the trigger loop region are controlling the rate
of RNA synthesis.22,23 Experiments in S. cerevisiae indicated
that the phenotypic consequences of rpb1 variants in yeast
might be concealed by transcript buffering24 and might
only become apparent under conditions of environmental
or nutrient stress.25 Experiments in Arabidopsis mutants
that encode truncated RPB1 with different sizes of short-
ened C-terminal domain (CTD) show disturbed cell cycling
control, demonstrating its importance in transcriptional
regulation of cell cycle genes.26 Despite its critical role in
transcription, POLR2A has not been implicated in human
disease thus far.
Here, we describe 16 individuals harboring de novo het-
erozygous genetic variants in POLR2A. We acknowledge
that, although the occurrence of de novo variants provides
an important clue toward variant pathogenicity,27 this
is not decisive28 because large-scale sequencing of indi-
viduals without severe pediatric disease has revealed
that protein-changing genetic variants are present in all
21,000 protein-encoding genes.29 Similarly, as individ-
uals carrying a variant in a certain gene are increasingly
found through gene-matching initiatives,30 phenotypic
overlap might merely reflect the general characteristics of
individuals undergoing whole-exome or whole-genome
sequencing (WES, WGS). In addition, neither the presence
nor the absence of evidence from functional analyses can
be used to prove or refute pathogenicity. This transition
of genetics from a dichotomous field to an exciting but
puzzling world full of shades of gray also offers new ave-
nues of study. Deep phenotyping analyses might help to
accurately expose the extent of the phenotypic overlap
to support pathogenicity and so might severity metrics
from population genetics. We here apply an iterative
process wherein we combine several lines of evidence,
including a detailed phenotypic analysis, an assessment
of variant severitymetrics, and structural biology and func-
tional analyses in both S. cerevisiae and HeLa cells to assess
the pathogenicity of the 16 identified variants in POLR2A
in detail.
Material and Methods
Phenotypes of Affected Individuals
The cohort was assembled through the GeneMatcher initiative.30
The inclusion criterionwas the detection of a de novo heterozygous
variant in POLR2A (GenBank: NM_000937.4) confirmed by either
clinical or research trio WES or WGS or by confirming the exclu-
sion of the heterozygous variant in both parents. Physicians first
provided a detailed phenotypic description of the individual. In
a second round, questions were asked regarding the specific clin-
ical features of the individual to further define the clinical overlap
among individuals. Additionally, doctors and parents together
performed a thorough evaluation of the individuals’ attainedmile-
stones by using items of the Denver Scale.31 We used these data to
assess both the rate of development over time and developmental-
domain-specific delays. To assess these focus points, we calculated
Z scores. The Denver Scale provides information on the fiftieth
(p50) and ninetieth (p90) percentiles of the age in months, at
which the normal population attains developmental milestones.
The ninetieth percentile corresponds to 1.28 standard deviations
(SDs). SD was calculated by (p90 – p50)/1.28. Z scores were calcu-
lated as (x – p50)/SD, wherein x is the month the individual at-
tained the developmental milestone. We performed the statistical
analysis in R programming language by using log10 transforma-
tion. All procedures followed were in accordance with the Helsinki
Declaration of 1975, as revised in 2000. The legal guardians for all
individuals agreed to the participation of their child in the study
and signed the appropriate consent forms, in agreement with
institutional and national legislation for the different centers.
Permission for publication of pictures was given separately.
Metrics of Variant Severity
Probability of intolerance to loss of function (pLI) scores for loss-
of-function variants and Z scores for synonymous and missense
variants were retrieved from the Genome Aggregation Database
(gnomAD) for POLR2A, as well as for the genes encoding other
pol II subunits. High pLI scores are indicative of intolerance of
loss-of-function variation, and Z scores are indicative of intoler-
ance of synonymous or missense variation.29 Additionally, ratios
of observed and expected variants were retrieved and acted as a
reflection of the degree to which variants within a gene are under-
reported, indicative of a survival disadvantage.
The CADD score is a tool for scoring the deleteriousness of sin-
gle-nucleotide variants and insertion and/or deletion variants in
the human genome.32 It integrates multiple annotations into
one metric by contrasting variants that survived natural selection
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with simulated variants. CADD scores were obtained for all
missense variants in gnomAD, as well as for the missense
and nonsense variants of the included individuals. A CADD
score >20 suggests pathogenicity because it indicates that the
variant is predicted to be among the 1% of most deleterious substi-
tutions that can be done to the human genome.
The distribution of genetic variants throughout POLR2A was
assessed on the basis of all POLR2A variants from gnomAD. The
interval length (number of amino acid positions) between two
sequential missense variants was calculated. A larger interval size
signifies a stretch devoid of missense variants and was considered
a possible index of pathogenicity for variants found within such
an interval. The mean and SD were calculated. The ‘‘desert Z
score,’’ indicating to which degree stretches within the gene are
devoid of missense variants, was calculated by the formula:
(stretch length – mean stretch length)/SD of stretch length.
Structural Evaluation of POLR2A Variants in Pol II
Pol II of S. cerevisiae is extensively studied by X-ray crystallography
and cryo-electron microscopy.7–11,13,14,16–20 Sequence conserva-
tion between human POLR2A and S. cerevisiae rpb1 is high, and
thus the available structures can serve as a model for the human
protein. To evaluate the putative consequences of POLR2A vari-
ants, the structures of RNA polymerase from Protein Data Bank
entries PDB: 1i6h, 1r5u, 1r9s, 1twf, 1y1v, 1y1w, 1y1y, 2e2h,
2nvq, 2nvz, 3gtj, 3gtm, 3how, 3hoy, 3po2, 3po3, 4a3l, 4a93,
4bbr, 4gwp, 4v1m, 4v1n, 4v1o, 5sva, 5xog, and 5xon were super-
imposed by overlaying the coordinates for rpb1with the algorithm
provided by BRAGI.33 Variants were mapped onto the structures
and evaluated for their putative impact on local protein folding
and enzymatic activity. Figures were prepared in the programs
Molscript34 and raster3D.35
Functional Evaluation of Variants in Pol II: POLR2A
Variants Expressed in S. cerevisiae
Six POLR2A variants were matched through GeneMatcher at the
time the experiment in S. cerevisiae was initiated; therefore six
POLR2A variants were functionally evaluated in S. cerevisiae. Plate
phenotyping of rpb1mutants was performed as described before.22
All of the S. cerevisiae strains that we used in this study are listed in
Table S1. They were derived from CKY283, CKY718, and CKY721.
Shortly, to generate mutant rpb1, point mutations in S. cerevisiae
rpb1 were introduced by PCR mutagenesis into the CEN LEU2
plasmid pRS315H3alt-RPB1* XmaI 1122-1123 T69 corrected. The
CEN LEU2 plasmids, containing mutant rpb1, were transformed
into an appropriate Leu strain with corresponding endogenous
rpb1 deletion and complemented with a CEN URA3 WT rpb1 sub-
unit gene expressing wild-type (WT) RPB1. Leuþ transformants
were patched on solid medium that lacked leucine and replica-
plated to medium that lacked leucine but contained 5-fluoroorotic
acid (Thermo Scientific) to select against cells maintaining RPB1
WTURA3 plasmids. Dsub1 or Ddst1þ rpb1mutant strains for direct
testing of double mutant phenotypes were constructed based on
CKY721 or CKY718, respectively, and analyzed in the same
fashion as rpb1 single mutants.
Assays were performed in biological triplicate in three different
backgrounds:WTbackground, absenceof TFIIS (Ddst1background),
and absence of the SUB1 transcription elongation factor (Dsub1
background). Transcriptional activity and genetic interactions
were determined. The assays with c.1592A>G (p.Asn531Ser)
(p.Asn517Seryeast) andc.2207C>T (p.Thr736Met) (p.Ser713Metyeast)
in the WT background were performed in sextuplicate to increase
the consistency of the results. p.Ala301Aspyeast was used as a
positive control for reduced transcriptional activity,36,37 and
p.Glu1230Lysyeast was used as a positive control for reduced genetic
interaction with TFIIS.38
For spot assays, overnight yeast peptone dextrose (YPD) cultures
from single colonies grown at 30C were diluted to an OD600 of
0.15. Five-fold serial dilutions were prepared and spotted on
indicated plates and grown for 3 to 6 days at 30C or 37C when
indicated. YPDmedium contained yeast extract (1%w/v final, [Bio-
sciences]), peptone (2% w/v final, [Biosciences]), dextrose (2% w/v
final), and bacto agar (2% w/v final, [Biosciences]). Alternative-
carbon-source YP media were YP raffinose (2% final w/v) and YP
raffinose (2% w/v final) plus galactose (1% w/v final). Synthetic
complete medium lacking leucine (SC-Leu) contained: 2gr/l drop-
out mix minus leucine (US Biological) and 6.71 gr/l Yeast Nitrogen
Base without amino acids and carbohydrate and with ammonium
sulfate (YNB) (US Biological) with 2% dextrose. Mycophenolic acid
(MPA, [Sigma-Aldrich]) was added to SC-Leu at 20 mg/mL final con-
centration from a 10 mg/mL stock in ethanol.
Functional Evaluation of Variants in Pol II: POLR2A
Variants Expressed in HeLa Cells
Nine POLR2A variants were matched through GeneMatcher at the
time the experiment in HeLa cells was initiated, therefore nine
POLR2A variants could be functionally evaluated in HeLa cells.
The open reading frame of human RPB1 was amplified by PCR
with a plasmid expressing RPB1 fusion with a B10 epitope, EGFP,
hRPB1, and six His residues36 and introduced into the pDONR201
cloning vector. The POLR2A coding sequence contained a point
mutation (AAC>GAC), which resulted in the replacement of
asparagine 792 by aspartate and resistance to a-amanitin.39 The
observed POLR2A point mutations in the included individuals
were introduced through the Quickchange protocol (Stratagene)
and verified by DNA sequencing. p.Lys812* was used as a represen-
tative of c.2098C>T (p.Gln700*) and c.2203C>T (p.Gln735*).
These two variants could not be designed because amino acid res-
idues Gln700 and Gln735 are localized in front of the built-in
resistance to a-amanitin (residue 792). p.Lys812* is expected to
result in a similar truncated version of the protein as p.Gln700*
and p.Gln735*. All RPB1 mutant proteins were tagged by GFP at
the N terminus. We created the stable doxycycline inducible cell
lines by transfecting pCDNA5/FRQT/TO and pOG44 into HeLa
FRT cells carrying the TET repressor by using polyethyleneimine
(PEI) and then antibiotic selection. HeLa cells were maintained
in DMEM containing 4.5 g/l glucose (GIBCO) supplemented
with 10% v/v heat-inactivated fetal bovine serum (FBS) (Sigma-
Aldrich) and 10 mM L-Glutamine (Sigma-Aldrich) under blastici-
din (5 mg/mL) (InvivoGen) and hygromycin B (400 mg/mL) (Roche
Diagnostics) selection.
The expression of GFP-tagged RPB1 was induced by treatment
with 1 mg/mL doxycycline for 24 h. Cells were spun down for
5 min at 400 g and washed with PBS. Next, cells were lysed
in whole-cell lysate (WCL) buffer (50 mM Tris-HCl [pH 8.0],
420 mM NaCl, 10 mM MgCl2, 10% glycerol, 0.1% NP40,
0.5 mM DTT, containing protease inhibitor cocktail), and lysates
were subjected to centrifugation at 400 g for 10 min. The superna-
tant was harvested and stored at 80C.
For the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazo-
liumbromide, Sigma-Aldrich) assay, doxycycline-inducible GFP-
RPB1amanitin resistant-expressingmutantHeLaFRTcellswere cultured
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for 3 to 5 days in the presence of 1 mg/mLdoxycycline to induce the
expression of themutants. Cells were seeded at 3,000 cells per well
in 100 ml normal DMEM in the presence of doxycycline in 96-well
plates. After a few hours, the mediumwas replaced by DMEMwith
doxycycline, and when indicated, 2.5 mg/mL a-amanitin (Boeh-
ringer Mannheim) was added. After 72 h of incubation, MTT was
added to a final concentration of 0.5 mg/mL.40 Cells were incu-
bated for 4 h under normal culturing conditions, then themedium
was carefully removed, and 100 mL DMSO was added to dissolve
the formazan crystals. The absorbance was measured at 570- and
630-nm wavelengths. Relative growth was calculated with the
equation (A570,sample – A630,sample)/(A570,untreated – A630,untreated).
GST Pull-Down
A GST-TFIIS recombinant expression construct41 was transformed
in BL21DE3; single colonies were picked, grown in LB þ ampi-
cillin, and induced for 3 h with 1 mM IPTG when cells reached
an OD600 of 0.6. Cells were pelleted by centrifugation and resus-
pended in lysis buffer (50 mM Tris-HCl [pH 7.0], 300 mM KCl,
2 mM EDTA, 20% sucrose, 0.1% Triton X-100, 0.5 mM PMSF,
and 1 mMDTT) containing 50 mL lysozyme (25 mg/mL) and incu-
bated for 10 min on ice. The suspension was freeze-thawed three
times and sonicated three times for 20 s. Cells were spun down
at 25,000 rpm for 45 min at 4C, and the supernatant was har-
vested and stored at 80C.
Glutathione-agarose (GA) beads (50% slurry) were washed three
times with binding buffer (20 mM Tris-HCl [pH 8.0], 50 mMNaCl,
1mMEDTA, 10% glycerol, 0.1mMZnCl2, 1mMDTT, and 0.5mM
PMSF). 20 mL GA beads (Sigma-Aldrich) per reaction were coated
with 25 mL GST-TFIIS lysate per reaction for 1 h at 4C. After
this, the GA beads were washed three times with binding buffer
and incubated with 300 mg HeLa FRT WCLs (unless otherwise
stated) in a final volume of 800 mL (50 mM NaCl at final concen-
tration) for 2 h at 4C while rotating. Beads were washed three
times and proteins were eluted in 15 mL sample buffer by a
5 min incubation at 95C.
Samples were lysed in sample buffer (160 mM Tris-HCl [pH 6.8],
4% SDS, 20% glycerol, and 0.05% bromophenol blue), run on an
8% SDS-PAGE, and transferred onto a PVDFmembrane. Themem-
brane was developed with the appropriate antibodies and ECL.
Antibodies came from the following sources: a-Tubulin (DM1A,
CP06, Calbiochem) and GFP (#632381, JL-8 Clontech).
Interactome Analysis with Mass Spectrometry
For interactome analysis, HeLa cells were grown, and nuclear ex-
tracts were prepared as described.42 The protein concentration
was determined with a Bradford assay. GFP affinity purification
was essentially performed as described.42 Protein extracts were
incubated with GFP-trap beads (Chromotek) or with blocked
agarose beads (Chromotek) as a negative control on a rotating
wheel at 4C with 1 mg input protein. Peptides were eluted from
the beads by 2 h trypsin incubation in elution buffer (100 mM
Tris-HCl [pH 7.5], 2M urea, and 10mMDTT). Eluate was collected,
and beads were eluted for a second time. Eluates were combined,
and trypsin digested overnight. Tryptic digests were desalted
with stage tips.43
The sampleswere cleanedupwith in-house-made stage tips. Pep-
tides were separated on a 30-cm pico-tip column (50 mm ID, New
Objective) in-house packed with 3 mm aquapur gold C-18 material
by applying a gradient (7%–80%ACN0.1%FA, 140min), delivered
by an easy-nLC 1000 system (LC120, Thermo Scientific), and elec-
tro-sprayed directly into an LTQ Orbitrap Mass Spectrometer (Ve-
los, ThermoScientific). Rawfileswere analyzedwith theMaxQuant
software version 1.5.1.0.; oxidation of methionine was set as vari-
able and carbamidomethylation of cysteinewas set as fixedmodifi-
cation. The human protein database of UniProt was searched with
the peptide and protein false discovery rate set to 1%.
Assessing Phenotype-Genotype Correlation
To assess phenotype-genotype correlation, we evaluated the
POLR2A variants for which support for pathogenicity was ob-
tained from positional and functional analyses and the variants
for which support for pathogenicity was obtained solely from po-
sitional analysis. These variants were considered ‘‘probable’’ to be
disease causing, indicating that we are strongly convinced that the
individuals’ genotypes are causing the individuals’ phenotypes.
We used the phenotypic features of the individuals harboring
these variants to delineate the phenotypic spectrum. For the
remaining variants, pathogenicity was assessed by determining
the degree of overlap. Phenotypic similarity was defined as the
presence of at least three phenotypic features of the five most
prevalent phenotypic features found in individuals harboring
‘‘probable’’ disease-causing variants in POLR2A. If the overlap in
phenotypic features was sufficient, these variants were considered
to be ‘‘possibly’’ disease-causing. If the phenotypic overlap was not
sufficient or could not be determined, the variant was classified as
‘‘unknown’’ whether this variant is disease-causing or not.
To correlate phenotypic severity to the predicted consequences
of the POLR2A variant and to find an explanation for the wide
phenotypic spectrum, an ad hoc severity score was conceived.44
It was calculated as follows: each tabulated item that was present
(þ) in the individual scored 1 point and each absent item ()
scored 0 points (Table 1). The items ‘‘sit without support,’’
‘‘walk well,’’ and ‘‘brain magnetic resonance imaging (MRI)
abnormalities’’ were calculated as follows: ‘‘sit without support’’
at <12 months scored 0 points, at 13–18 months scored 1 point,
at 19–30 months scored 2 points, and at >30 months scored
3 points; ‘‘walk well’’ at <24 months scored 0 points, at
25–30 months scored 1 point, at 31–48 months scored 2 points,
and at >48 months scored 3 points; no brain abnormalities
scored 0 points, wide ventricles and/or delayed myelination
scored 1 point, and white matter abnormalities scored 2 points.
A severity score of <12 points indicated the phenotype was mild,
a score of 12–17 indicated moderate, a score of 18–23 indicated
severe, and a score of >23 points indicated profound.
Results
Phenotypes of Affected Individuals
Sixteen individuals, all harboring ultra-rare, de novo
heterozygous variants in POLR2A, were located via
GeneMatcher.30 Other (genetic) causes of the phenotypes
of the included individuals were thoroughly excluded.
The cohort included three individuals with truncating
variants (two stop codons and one frameshift), three
individuals with in-frame deletions (IF deletion), and
ten individuals with missense variants. Portraits of
the individuals are shown in Figure 1A, clinical charac-
teristics of all individuals are summarized in Table 1,
and extended individual reports can be found in the
Supplemental Data. In summary, eleven individuals were
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Table 1. Characteristics of Individuals Harboring a Heterozygous De Novo Variant in POLR2A
Individual 5 6 8 12 13 1 16
Variant p.Gln700* p.Gln735* p.Ser755del p.Leu1124Pro p.Lys1125del p.Pro371Leu p.Pro1767fs
Sex m f m f m f m
Gestation (weeks) 42 28 Term 38 37 41 41
Age (years) 17 13 3 4 7 7 9
General hypotonia  þ þ þ þ þ þ
Strabismus  þ þ þ þ þ 
Frog position infancy   þ þ   
Decreased endurance   þ þ þ  þ
Feeding difficulties  þ  þ  þ þ
Recurrent RTI   þ þ   þ
High forehead þ þ þ  þ  þ
Disturbed sleeping þ      
Gastro-esoph. reflux  þ     
High palate þ    þ NA 
Delayed visual matur. þ      
Microcephaly       
Brachyplagiocephaly     þ  þ
Muscle atrophy       
Hypertelorism     þ þ þ
Teeth misalignment  þ  þ þ  þ
Decreased vision þ     þ 
Stagnation episodes       
Inguinal hernia       
Decreased fetal movem.   NA þ   
Autistic behavior þ   NA   
(Continued on next page)
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Table 1. Continued
Individual 5 6 8 12 13 1 16
Aggressive behavior       
Failure to thrive      þ 
Pectus excavatum       
Epilepsy       
Sit, no support (months) 7 12 NA 12 18 24 24
Walk well (months) 18 30 >36 23 24 72 28
Brain MRI abnormalities  Cerebellar atrophy, inferior vermis,
small pons, megacisterna magna, and
slightly small corpus callosum
Delayed myelination Delayed myelination Delayed myelination  
Severity score 6 9 9 9 10 11 11
Severity class Mild Mild Mild Mild Mild Mild Mild
Individual 4 11 10 15 9 14 2 7 3
Variant p.Tyr669del p.Tyr1109His p.Ile848Thr p.Arg1603His p.Met769Thr p.Asn1251Ser p.Ile457Thr p.Thr736Met p.Asn531Ser
Sex f m f f m f m f m
Gestation 41 40 41 Term 41 40 40 39 30a
Age (years) 11 6 13 7 18 6 4 9 0
General hypotonia þ þ þ þ þ þ þ þ NA
Strabismus  þ  þ þ þ þ þ NA
Frog position infancy þ þ þ þ þ þ þ þ NA
Decreased endurance þ NA þ  þ þ þ þ NA
Feeding difficulties þ  þ  þ þ þ þ NA
Recurrent RTI*  þ  þ  þ þ þ NA
High forehead     þ  þ  
Disturbed sleeping þ   þ þ þ þ þ NA
Gastro-esoph. reflux þ  þ   þ þ þ NA
High palate     þ  þ þ Cleft
(Continued on next page)
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Table 1. Continued
Individual 4 11 10 15 9 14 2 7 3
Delayed visual matur. þ   þ þ  þ þ NA
Microcephaly  þ  þ þ þ  þ 
Brachyplagiocephaly   þ   þ þ  
Muscle atrophy   þ  þ  þ þ NA
Hypertelorism     þ  þ  þ
Teeth misalignment þ        
Decreased vision    þ þ   þ NA
Stagnation episodes þ þ     þ þ NA
Inguinal hernia þ    þ  þ þ NA
Decreased fetal movem.      þ þ  
Autistic behavior þ   þ þ    NA
Aggressive behavior þ  þ þ  þ   NA
Failure to thrive      þ  þ NA
Pectus excavatum þ    þ þ   NA
Epilepsy  þ  þ    þ NA
Sit, no support (months) 11 24 24 Attained 14 48 23 >108
Walk well (months) 26 >72 >156 56 27 65 >55 >108
Brain MRI abnormalities  Wide ventricles,
increased T2 signals
in nuclei pallidi
Wide ventricles,
cystic area in
periventricular
white matter
Wide ventricles, thin
corpus callosum,
bilateral loss of
white matter
Delayed
myelination
Megacisterna
magna
Delayed myelination,
wide ventricles
Wide ventricles
and sulci, cerebellar
volume loss, abnormal
globus pallidus
Corpus callosum
agenesis
Severity score 14 14 15 16 19 21 23 25 NA
Severity class Moderate Moderate Moderate Moderate Severe Severe Severe Profound
Abbreviations are as follows: m ¼ male, f ¼ female, NA ¼ not available, and RTI ¼ respiratory tract infections.
aTermination of pregnancy.
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Milestone attained
Yes
No
Language
Personal Social
0 3 6 9 12 15 18 0 3 6 9 12 15 18 0 3 6 9 12 15 18 0 3 6 9 12 15 18
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Ind. 5; p.Gln700* Ind. 8; p.Ser755del Ind. 12; p.Leu1124Pro Ind. 13; p.Lys1125del Ind. 1; p.Pro371Leu Ind. 16; p.Pro1767fs
Ind. 4; p.Tyr669del Ind. 11; p.Tyr1109His Ind. 10; p.Ile848Thr Ind. 15; p.Arg1603His
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Ind. 9; p.Met769Thr Ind. 14; p.Asn1251Ser Ind. 2; p.Ile457Thr Ind. 7; p.Thr736Met
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Ind. 6; p.Gln735*
Not available
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pe Milestone group
Fine motor
Gross motor
Ind. 5; p.Gln700* Ind. 8; p.Ser755del Ind. 12; p.Leu1124Pro Ind. 16; p.Pro1767fsInd. 6; p.Gln735* Ind. 13; p.Lys1125del
Ind. 4; p.Tyr669del Ind. 11; p.Tyr1109His Ind. 10; p.Ile848Thr Ind. 15; p.Arg1603His
Ind. 9; p.Met769Thr Ind. 14; p.Asn1251Ser Ind. 2; p.Ile457Thr Ind. 7; p.Thr736Met
Ind. 1; p.Pro371Leu
Not available
Figure 1. Photos and Attainment of Developmental Milestones of Individuals with POLR2A Variants
(A) Photos of 13 of the 16 individuals (ind.) harboring a de novo variant in POLR2A, in order of severity score.
(B) Attained and unattained developmental milestones during the first 18 months of life for 14 of the 16 individuals harboring a de novo
variant in POLR2A, in order of severity score. For each milestone, Z scores were calculated indicating the delay in attaining that mile-
stone. The higher the Z scores, the greater the developmental delay. The figure demonstrates that in individuals with a mild phenotype,
developmental Z scores are mostly <10, in individuals with a moderate phenotype, developmental Z scores are <20, and in individuals
with a severe phenotype, developmental Z scores can even reach 30. In addition, among the individuals with a severe phenotype, rela-
tivelymore (andmore early) developmentalmilestones were not attained by the individual. Individual 3 (p.Asn531Ser) was not included
in this figure because the pregnancy was terminated.
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born after a generally uneventful pregnancy and delivery
at term and had a normal birth weight and normal
perinatal events. Decreased fetal movements were noted
in three pregnancies, and one female was born preterm
at 28 weeks. One pregnancy carrying a male fetus (individ-
ual 3, p.Asn531Ser) was terminated because of corpus
callosum agenesis, frontonasal dysplasia, and a cleft lip.
The most frequent early and usually striking pheno-
typic feature was hypotonia. It was noted in fourteen
individuals and was profound in nine (Figure S1), evi-
denced by decreased muscle tone, a frog-like posture
in infancy, and reduced spontaneous movements but
normal tendon reflexes. Muscles were considered atrophic
in four individuals. A muscle biopsy, on suspicion of a
myopathy, was performed in four individuals, but the re-
sults were inconclusive. In addition, there were symptoms
and signs commonly associated with hypotonia; these
signs included brachyplagiocephaly (in five individuals),
a high arched palate (in five individuals), pectus excava-
tum (in three individuals), recurrent respiratory tract infec-
tions (in eight individuals), and inguinal hernia (in four in-
dividuals). The majority of individuals (ten) had feeding
difficulties, with gastro-esophageal reflux (in six individ-
uals), resulting in failure to thrive (in three individuals).
Ocular signs included strabismus (in eleven individuals)
and delayed visual maturation (in six individuals), result-
ing in decreased vision (in five individuals). Moderate to
severe sensorineural hearing loss was reported in two
individuals, and conductive hearing loss due to recurrent
respiratory tract infections was reported in one individual.
Dysmorphic features were generally mild and non-distinc-
tive; these included a high forehead (in seven individuals),
hypertelorism (in six individuals), and tooth misalignment
(in five individuals), which is defined as an abnormal
spacing of the teeth without missing any teeth. Brain
MRI performed in eleven individuals revealed white matter
abnormalities (in ten individuals), ranging from delayed
myelination (in five individuals) to wide lateral ventricles,
putatively due to white-matter loss (in four individuals). A
thin corpus callosum, a feature consistent with the loss
of white matter was noted in two individuals. Addition-
ally, three individuals had cerebellar abnormalities. Severe
epilepsy was reported in three individuals. Eight individ-
uals had sleeping difficulties. Autistic (in four individuals)
and aggressive (in four individuals) behavior, including
extreme behavior such as pica (eating dung), was reported.
Hypotonia tended to improve over time, albeit slowly.
Later in life, endurance was diminished (in ten individ-
uals). A delayed development involving all domains
was noted in all individuals and ranged from mild to
severe. The severity of the delay was evaluated by calcu-
lating Z scores on the basis of the acquisition of develop-
mental milestones, with higher Z scores indicating later
acquisition of milestones. The individuals’ developmental
Z scores were stable over time, consistent with a gradual
development without developmental catch-up or decline.
The Z scores between domains were similar, arguing
against developmental-domain-specific delays (Figure 1B).
The degree of delay appeared to correlate with the degree
of hypotonia. Temporary loss of milestones was reported
in four individuals, usually following an infection. Addi-
tional metabolic investigations ruled out known inborn
errors of metabolism.
Variant Severity Metrics
Large-scale genetic data retrieved from gnomAD from indi-
viduals without severe pediatric disease indicate that
POLR2A is intolerant of deleterious, heterozygous, pro-
tein-changing variants. This is evidenced by a maximal
pLI score (1.0) and a very low observed/expected ratio
(0.08), indicating intolerance of loss of function variants
(Table S2). Moreover, the Z score (7.13) for missense vari-
ants is one of the highest of all human protein-coding
genes, suggesting that subtle heterozygous changes can
also cause a survival disadvantage (Table S2).
An assessment of conservation across species (Figure 2A)
revealed that nine out of ten missense variants affect high-
ly conserved amino acid residues (Figure 2B). However, this
variant property fails to be discriminatory because the
overall degree of conservation of POLR2A is extremely
high (Figure 2A). In the pol II core, roughly 50% of residues
are identical, and an additional 20% are highly similar be-
tween humans and yeast. Similarly, the CADD scores of the
individuals’ variants were all above the arbitrary cut-off of
20, indicating that these variants are predicted to be in the
1% of the most deleterious substitutions that can be done
to the human genome and thereby suggesting pathoge-
nicity;32 however, most of the CADD scores of the variants
observed in the gnomAD cohort of individuals without
severe pediatric disease (Figure S2) were also above the
cut-off. Thus, these indices of pathogenicity at the
amino-acid level lack discriminative power.
Next, we evaluated whether pathogenicity was related to
the variants’ positions within POLR2A. The observation
that the individuals’ variants were found throughout the
gene argued against a domain-specific deleteriousness. In
line with Lelieveld et al. and Havrilla et al.,45,46 we hypoth-
esized that the distribution of protein-changing POLR2A
variants observed in the gnomAD cohort of individuals
without severe pediatric disease—apparently tolerated
well enough and therefore more likely to be found at posi-
tions tolerant to change—could conversely unveil areas
intolerant to change. S. cerevisiae tolerates truncations of
the CTD region comprising up to 50% of its 26 heptad re-
peats in rpb1, the ortholog of POLR2A.47,48 This strongly
suggests that the human POLR2A CTD region, consisting
of 52 repeats, might be equally tolerant to the loss of a pro-
portion of the heptad repeats. Indeed, the majority of the
truncating variants reported in gnomAD—and none of
the truncations found in these individuals—are positioned
in the distal portion of the CTD region (Figure 2A). In addi-
tion, the density of POLR2A missense variants reported in
gnomAD is also highest in the CTD region, not only in
the distal part but throughout the whole repeat region,
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Figure 2. Structural Evaluation of POLR2A Variants
(A) RPB1 is represented; the core and the C-terminal heptad repeats are shown as bars. Functional elements are highlighted in dark blue
and are labeled underneath. The positions of gained stop codons, frameshifts, in-frame deletions (IF deletion), missense mutations, and
synonymous mutations at the protein level, as reported in the gnomAD database, are indicated by vertical black strokes. The length of
the stroke represents the number of different mutations observed at the DNA level in the corresponding codon. The individuals’ variants
are indicated by red strokes and are labeled. Stretches devoid of missense mutations are highlighted by a yellow background and are
(legend continued on next page)
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indicating that a putative functional loss of a single heptad
repeat is tolerated, regardless of its position.
Within the remaining part of POLR2A, missense variants
are strikingly unevenly distributed when compared with
synonymous variants (Figure 2A). In line with our hypoth-
esis, although the median distance between variants is
only two amino acid residues, several stretches, the longest
of which spans about 80 amino acid residues, that are
devoid of missense variants are observed (Figure 2A). These
stretches devoid of missense variants correspond to a
number of known functionally important regions of
the protein. Nine out of ten missense variants from
our individuals, two out of three in-frame deletions, and
two out of three truncating variants were positioned
within these stretches with desert Z scores that fell be-
tween 2.9 and 11.9, indicating intolerance to change in
these regions and thereby supporting pathogenicity
(Figure 2A and Table 2).
Structural Evaluation of POLR2A Variants in Pol II
Most of the amino residues affected in the individuals have
identical or similar residues in the S. cerevisiae counterpart
(Figures 2A, 2B, and 2J), for which high-resolution struc-
tural information is available. This allows for structural
evaluation of the variants in pol II. Variants p.Gln700*
and p.Gln735* result in a truncation that leads to missing
more than half of the protein. If translation is not already
prevented by nonsense-mediated decay, the truncated
protein is still not expected to form a stable fold with
the second largest and core subunit of pol II, RPB2, and it
lacks binding sites for several other subunits (Table 2). It
is therefore most likely that effects observed with
p.Gln700* and p.Gln735* result from RPB1 haploinsuffi-
ciency. In support of this, mass spectrometry analyses
showed that the variant p.Lys812* (which we used as a
representative of p.Gln700* and p.Gln735* because
p.Lys812* is similarly truncated, seeMaterial andMethods)
could only associate with RPABC3 (POLR2H) but not with
any of the other pol II subunits (Figure 3C). Variant
c.5298dup (p.Pro1767fs) is located in the proximal half
of the CTD and results in the loss of the last 200 amino
acids, corresponding to about 50% of the heptad repeats.
The folding of the polymerase core is not expected to be
affected by this truncation.49,50 Therefore, p.Pro1767fs is
expected to form pol II, but because the CTD region of
RPB1 is too short, pol II function might be affected.
The IF deletions c.2006_2008delACT (p.Tyr669del)
(p.Phe646yeast) and c.2262_2264delCTC (p.Ser755del)
(p.Leu732yeast) are localized in close proximity to the
quay, whereas the IF deletion c.3373_3375delAAG
(p.Lys1125del) (p.Lys1102yeast) is localized in the trigger
loop (Figures 2C–2F). The deletions are predicted to alter
the local protein fold and to have a strong impact on
catalytic activity. It is difficult to predict to what extent
the overall protein fold and the ability to assemble into
pol II are impaired, but such impairment would shift the
properties from severe dominant-negative tomild haploin-
sufficiency. In case of p.Ser755del, mass spectrometry data
showed that the interaction with other pol II subunits is
largely unaltered, showing that formation of the pol II
complex is not affected (Figure 3C).
Interestingly, most missense variants are centered
around the catalytic site (Figures 2C–2F and Table 2):
c.3325T>C (p.Tyr1109His) (p.Phe1086yeast) and
c.3371T>C (p.Leu1124Pro) (p.Leu1101yeast) are positioned
in the trigger loop, p.Thr736Met (p.Ser713yeast) in the
opposing quay, c.1370T>C (p.Ile457Thr) (p.Leu443yeast)
and c.2306T>C (p.Met769Thr) (p.Met746yeast) in the
labeled by Roman numerals. The degree of conservation in humans and S. cerevisiae is depicted underneath, whereby each identical
amino acid is represented by a vertical black stroke.
(B) Conservation across species of amino acid residues that are changed in the individuals affected bymissensemutations. p.Arg1603His
is not conserved and is localized in the region between the pol II core and the heptad repeats, and p.Pro1767fs is localized in the heptad
repeat region. For these regions, alignments are not reliable.
(C) A space-fillingmodel of the elongating form of pol II from S. cerevisiaewith TFIIS in ribbon representation in red. Subunits other than
RPB1 are shown in dark gray. RPB1 is shown in light gray; the positions of individuals’ variants are highlighted inmagenta, and stretches
devoid of missense variants are shown in shades of yellow labeled by Roman numerals as in (A). The incoming nucleotide is shown as a
space-fillingmodel in orange. The template strand, the coding strand, and the nascentmRNA are shown as backbone trace in gray, black,
and orange, respectively.
(D) Same as in (C), but omitting subunits other than RPB1. Only the RPB1 stretches devoid of missense variants and the positions of
individuals’ variants are shown, and all other parts of RPB1 have been omitted. The 3D-envelope of RPB1 is projected in light gray
on the background plane.
(E) Same as in (D), but additionally omitting the RPB1 stretches devoid of missenses variants. The Ca-atoms of amino acid residues
affected in individuals’ variants are shown as magenta spheres.
(F) Detailed view at the catalytic center of pol II. The coding strand in dark gray, the template strand in light gray, the nascent mRNA in
orange, and the incoming nucleotide in red are shown as a space-filling model. The bridge helix is shown as a rod, and selected other
parts of RPB1 as backbone trace. The trigger loop is shown in its open and closed conformation in light and dark blue, respectively. Side
chains of amino acid residues affected in individuals with a missense variant and of some residues known to be of catalytic importance
are shown in ball-and-stick representation. The Ca-atoms of amino acid residues affected by IF deletions or the gain of a stop codon are
shown as spheres in magenta.
(G) The environment of residue Pro357. Elements from RPB1, subunit 2, and the pol II subunit RPB11 are depicted in light blue, green,
and orange, respectively. Hydrogen bonds are indicated by dotted lines
(H) The environment of residue Asn517. Elements of RPB1 are shown in blue
(I) The environment of residue Asn1232. Elements of RPB1 and TFIIS are shown in blue and red, respectively. Putative hydrogen bonding
partners for Asn1232 in TFIIS are marked by an asterisk.
(J) A table assigning amino acid residues that are affected in individuals to the corresponding residues of RPB1 in S. cerevisiae.
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Table 2. Lines of Evidence for Pathogenicity of Variants in POLR2A
Individual 1 2 3 4 5 6 7 8
Variant p.Pro371Leu p.Ile457Thr p.Asn531Ser p.Tyr669del p.Gln700* p.Gln735* p.Thr736Met p.Ser755del
cDNA change c.1112C>T c.1370T>C c.1592A>G c.2006_2008delACT c.2098C>T c.2203C>T c.2207C>T c.2262_2264delCTC
Phenotype
Severity score 11 23 NA 14 6 9 25 9
Severity class Mild Severe Moderate Mild Mild Profound Mild
Metrics of Variant Severity
Yeast conservation Identical Similar Identical NA NA NA Similar NA
Amino acid stretch 366–375 448–470 523–532 664–671 689–715 689–715 717–797 717–797
Stretch length 9 22 9 7 26 26 80 80
Desert Z score 0.8 2.9 0.8 0.5 3.5 3.5 11.9 11.9
Structural Evaluation
Position Funnel Catalytic site – Close to quay Quay Quay Quay Quay
Protein folding – – – Locally altered Loss Loss – Locally altered
Dominant negative – Expected – – – – Expected –
Haploinsufficiency – – – Putative Expected Expected – Putative
Functional Evaluation
Yeast mutation NA Leu443Thr Asn517Ser NA NA NA Ser713Met Leu732del
Yeast growth (WT) NA Normal Normal NA NA NA Normal Normal
Yeast growth (Ddst1; Dsub1) NA Aberrant Normal NA NA NA Aberrant Aberrant
Yeast galactose sensitivity NA Yes No NA NA NA Yes Yes
Yeast MPA sensitivity NA Yes No NA NA NA Yes Yes
HeLa cell viability NA ¼ ¼ NA YYY YYY YYY YYY
Disease-causing variant Possible Probable Unknown Possible Probable Probable Probable Probable
Individual 9 10 11 12 13 14 15 16
Variant p.Met769Thr p.Ile848Thr p.Tyr1109His p.Leu1124Pro p.Lys1125del p.Asn1251Ser p.Arg1603His p.Pro1767fs
Mutation c.2306T>C c.2543T>C c.3325T>C c.3371T>C c.3373_3375delAAG c.3752A>G c.4808G>A c.5298dup
(Continued on next page)
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Table 2. Continued
Individual 9 10 11 12 13 14 15 16
Phenotype
Severity score 19 15 14 9 10 21 16 11
Severity class Severe Moderate Moderate Mild Mild Severe Moderate Mild
Metrics of Variant Severity
Yeast conservation Identical Identical Similar Identical NA Identical Other NA
Amino acid stretch 717–797 836–877 1086–1135 1086–1135 1086–1135 1218–1254 1603–1604 1766–1769
Stretch length 80 41 49 49 49 36 1 3
Desert Z score 11.9 5.8 7.1 7.1 7.1 5.0 0.4 0.1
Structural Evaluation
Position Catalytic site Bridge helix Trigger loop Trigger loop Trigger loop TFIIS interact. – Hepta repeats
Protein folding – – – – Locally altered – – Core normal
Dominant negative Expected – Expected Expected – – – –
Haploinsufficiency – – – – Putative – – –
Functional Evaluation
Yeast mutation NA NA NA Leu1101Pro NA Asn1232Ser NA NA
Yeast growth (WT) NA NA NA Aberrant NA Normal NA NA
Yeast growth (Ddst1; Dsub1) NA NA NA Aberrant NA Normal NA NA
Yeast galactose sensitivity NA NA NA Yes NA No NA NA
Yeast MPA sensitivity NA NA NA Yes NA No NA NA
HeLa cell viability NA NA NA YYY NA ¼ ¼ NA
Disease-causing variant Probable Possible Probable Probable Probable Probable Possible Probable
Abbreviations are as follows: NA ¼ not available, WT ¼ wildtype, and MPA ¼ mycophenolic acid. A dash indicates results were unknown.
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nucleotide binding site, c.1112C>T (p.Pro371Leu)
(p.Pro357yeast) in the funnel (Figure 2G), and c.2543T>C
(p.Ile848Thr) (p.Ile825yeast) in the bridge helix (Figures
2C–2F and Table 2). These POLR2A variants are likely to
reduce the transcriptional pausing, elongation, and/or
back-tracking activities of pol II without affecting tran-
scription initiation. Indeed, all tested missense RPB1 vari-
ants were found to interact with other pol II subunits,
indicating that complex formation is largely unaltered
(Figure 3C).
The missense mutation c.3752A>G (p.Asn1251Ser)
(p.Asn1232yeast) is located distantly from the catalytic
site, but it is localized in the interaction surface for
transcription-elongation factor TFIIS, which is required
for back-tracking of pol II due to elongation blocks or
nucleotide mis-incorporation (Figure 2I). TFIIS interaction
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Figure 3. Functional Evaluation of POLR2A Variants
(A) A growth assay in S. cerevisiae of six rpb1 mutants: p.Ile457Thr (p.Leu443Thr), p.Asn531Ser (p.Asn517Ser), p.Thr736Met
(p.Ser713Met), p.Ser755del (p.Leu732del), p.Leu1124Pro (p.Leu1101Pro), and p.Asn1251Ser (p.Asn1232Ser) are compared to wild
type (WT). p.Ala301Asp demonstrates a positive control for reduced transcriptional activity, and p.Glu1230Lys demonstrates a positive
control for reduced genetic interaction with TFIIS. YPD 30C depicts growth under normal circumstances, and YPD 37C depicts growth
under stress induced by increased temperature. YPRaf/Gal day 4 and day 6 depict growth under stress induced by increased inappropriate
GAL 30 termination on day 4 and day 6 of culture, respectively. SC-LEUþMPA day 4 and day 6 depict growth under stress induced by the
lack of leucine and the addition of mycophenolic acid (MPA) on day 4 and day 6 of culture, respectively.
(B) HeLa cell viability. The individuals’ variants were introduced in an a-amanitin-resistant version of POLR2A (amaR) and expressed
from a doxycycline-inducible promoter as a GFP fusion construct in HeLa cells. After the induction of expression, endogenous pol II
was left untreated (dark gray bars) or inhibited by the application of a-amanitin (light gray bars), and cell viability was determined. Error
bars represent the standard deviation. p.Lys812* was used as a representative of p.Gln700* and p.Gln735* because it is similarly
truncated (see Material and Methods).
(C) Interactome analysis of wild-type (WT) and mutant versions of RPB1 using mass spectrometry. Nuclear extracts from HeLa cells ex-
pressing GFP-taggedWTormutant versions of RPB1 were used for precipitations with control agarose beads () or GFP-affinity beads (þ)
in triplicate. In total, 1,133 proteins were identified by more than two peptides via intensity-based absolute quantification (IBAQ) mass
spectroscopy. Known members of pol II (highlighted) and a random selection of 5% of the other proteins are shown. The summed
peptide intensities of identified proteins were logarithmically transformed to the basis of ten and are represented by shades of gray.
Note, intensities smaller than 104 are not obtained due to technical constrains. p.Lys812* was used as a representative of p.Gln700*
and p.Gln735*.
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mutants of pol II would have both an increased error rate
and reduced elongation rates. The consequences of the
missense variants p.Asn531Ser (p.Asn517yeast) (Figure 2H)
and c.4808G>A (p.Arg1603His) are more difficult to pre-
dict. p.Asn531 is not directly associated with a structural
element involved in catalysis (Figure 2H). p.Arg1603His
is localized in the region that connects the RPB1 core to
the heptad repeats (Figure 2A). No structural information
is available for this region, and it is only partially conserved
between human and S. cerevisiae RPB1 (Figure 2A).
Altogether, structural evaluation of POLR2A variants
resulted in the expected haploinsufficiency for p.Gln700*
and p.Gln735*, putative haploinsufficiency for the IF
deletions, and an expected dominant-negative effect
for the missense variants p.Ile457Thr, p.Thr736Met,
p.Met769Thr, p.Tyr1109His, and p.Leu1124Pro (Table 2).
Functional Evaluation of POLR2A Variants in Pol II
The consequences of POLR2A variants on pol II function
were investigated in S. cerevisiae and HeLa cells for six
and nine of the individuals’ variants, respectively, repre-
senting the whole clinical spectrum (Table 2).
In S. cerevisiae, in a WT genetic background, normal
growth was observed in all but one variant (p.Leu1124Pro
[p.Leu1101Proyeast]) under optimal conditions, as well as
under temperature stress conditions (YPD at 37C) (Table
2 and Figure S3). In genetic backgrounds lacking transcrip-
tion factors Dst1 (yeast ortholog of TFIIS) or Sub1 (yeast or-
tholog of PC4), aberrant growth surfaced in four out of six
variants (p.Leu1124Pro [p.Leu1101Proyeast], p.Ile457Thr
[p.Leu443Thryeast], p.Thr736Met [p.Ser713Metyeast], and
p.Ser755del [p.Leu732delyeast]) when compared with WT
and the positive controls for Ddst1 (p.Glu1230Lysyeast)
(Table 2 and Figure S3) and Dsub1 (p.Ala301Aspyeast)
(Figure 3A and Table 2). A read-through transcription assay,
in which GAL7 production is inhibited in WT (gal10D56)
cells, causing galactose sensitivity on YPRaf/Gal,23 also
shows aberrant growth for these four variants (Figures 3A
and S3 and Table 2). Although milder, these four variants
also exhibited aberrant growth when exposed to the nucle-
otide synthesis inhibitor mycophenolic acid (MPA) in one
or both of these genetic backgrounds (Figures 3A and S3
and Table 2). Disturbances in both genetic backgrounds
(Ddst1 and Dsub1) are suggestive of reduced transcriptional
fidelity.
Cell viability was assessed with an MTT (3-(4,5-dime-
thylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) assay in
doxycycline-inducible GFP-RPB1amanitin resistant-expressing
mutant HeLa FRT cells, in which the endogenous WT
RPB1 was annihilated with the pol-II-specific drug
a-amanitin. Cell viability was grossly reduced in mutants
expressing variants p.Thr736Met, p.Ser755del, p.Lys812*,
and p.Leu1124Pro (Figure 3B), supporting the pathoge-
nicity of these variants. No significant effects were seen for
the variants p.Ile457Thr, p.Asn531Ser, p.Asn1251Ser, and
p.Arg1603His (Figure 3B). For all mutants, the amounts of
RPB1 protein were similar to the protein amount of WT
RPB1 (Figure S4). Binding affinity toward TFIIS, a key
transcription factor, was unaffected for all mutants. This
included the p.Asn1251Ser mutant, despite its location in
theTFIISbinding site (FigureS4). Taken together, the charac-
terization in S. cerevisiae andMTTcell viability in HeLa cells
provide evidence for pathogenicity of variants located close
to the catalytic core, but not for p.Asn531Ser, p.Asn1251Ser,
and p.Arg1603His (Table 2).
Assessing Phenotype-Genotype Correlation
To delineate the phenotypic spectrum that could be
attributed to POLR2A variants, we focused on variants
considered to be probable to cause disease. Positional and
functional evaluation of the POLR2A variants’ effects on
pol II function supported pathogenicity of the missense
variants p.Ile457Thr, p.Thr736Met, and p.Leu1124Pro, as
well as of the IF deletion p.Ser755del and the truncated
variants p.Gln700* and p.Gln735* (Table 2), and solely
positional evaluation supported pathogenicity for the
missense variants p.Met769Thr, p.Ile848Thr, p.Tyr1109His,
and p.Asn1251Ser and for the IF deletion p.Lys1125del
(Table 2). The phenotypic features of the eleven individuals
harboring these variants were used to delineate the POLR2A
phenotypic spectrum (Table 2). These phenotypic features
included profound general hypotonia (in ten individuals),
as evidenced by a frog position in infancy (in eight individ-
uals), strabismus (in nine individuals), decreased endurance
(in eight individuals), and feeding difficulties (in seven
individuals) (Table 1). The pathogenicity of the remaining
variants was assessed by determining the degree of pheno-
typic overlap. Individual 1 (p.Pro371Leu), individual 4
(p.Tyr669del), individual 15 (p.Arg1603His), and individ-
ual 16 (p.Pro1767fs) presented with clinical phenotypes
clearly fitting the phenotypes of the other POLR2A
individuals because all had at least three of the five most
prevalent POLR2A symptoms (Table 1), and therefore these
variants were considered to be possibly disease-causing
(Table 2). For individual 3 (p.Asn531Ser), the phenotypic
overlap could not be assessed because the pregnancy had
been terminated, and it is thus unknown whether this
variant is disease-causing (Table 2).
We noted that the degree of developmental delay corre-
lated with the predicted consequences of the variant: in
the individuals with variants predicted to cause haploinsuf-
ficiency, we noted relatively low Z scores (mean Z score
1.74 5 3.13), but variants expected to cause a dominant-
negative effect were associated with appreciably higher Z
scores (median Z score 4.23 5 3.96, p < 0.0001) and thus
with more severe delays (Figure 1B). To assess this further,
we calculated a severity score that summarizes the severity
of the clinical phenotype for POLR2A. The severity scores of
individuals harboring variants with expected or putative
haploinsufficiency (mean severity score 10, range 6–14
points) were lower than in individuals harboring variants
with expected dominant-negative effects (mean severity
score 17, range 6–25 points, Table 1). This suggests that a
missense mutation exerting a dominant-negative effect
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is more likely to result in a severe phenotype (severity
score >15) than a mutation inducing haploinsufficiency.
Discussion
In this study, we applied an iterative approach to assess the
pathogenicity of identified variants in POLR2A. The main
argument supporting the pathogenicity of the identified
variants is that all variants occurred de novo.27 In addition,
POLR2A is, overall, very intolerant of deleterious, heterozy-
gous, protein-changing variants. Furthermore, nine out of
ten missense variants affected highly conserved amino
acid residues that are localized at important functional
regions of the gene. Functional analyses support path-
ogenicity of the variants p.Ile457Thr, p.Thr736Met,
p.Gln700*, p.Gln735*, p.Ser755del, and p.Leu1124Pro,
although we note that both yeast and HeLa cells are model
systems that might not fully recapitulate the complex
developmental disease of the individuals reported here.
Although we did not demonstrate support from functional
analyses for the variants p.Asn531Ser and p.Asn1251Ser,
the pathogenicity of p.Asn1251Ser is strongly supported
by the conservation of the amino acid residue and the
importance of the region for interaction with TFIIS. Alto-
gether, on the basis of the results of both predictive and
functional analyses, eleven variants were classified as prob-
ably disease-causing (Table 2).
Deep phenotyping, including quantification of pheno-
typic severity of the individuals, allowed us to delineate
the phenotypic spectrum that could be ascribed to the path-
ogenic POLR2A variants. The severe end of the spectrum
is characterized by profound infantile-onset hypotonia
and developmental delay, and is further accompanied by
strabismus, decreased endurance, and feeding difficulties.
Determining thedegreeof clinical overlapbetween the indi-
viduals harboringprobably disease-causing variants and the
remaining individuals allowed us to classify four additional
variants as possibly disease-causing. Additional support for
the pathogenicity of the variant p.Asn531Ser, other than
its de novo occurrence, conservation across species, and a se-
vere phenotype, could not be determined, so this variant
was classified as of unknown significance.
Thus, the iterative process described here allowed us to
delineate pathogenicity for the majority—but not all—of
the individuals’ variants. Given the current knowledge,
evidence that either confirms or excludes pathogenicity
for four possibly disease-causing variants and the one
variant of unknown significance will be hard to obtain.
This is illustrated by the variant p.Arg1603His. Support
for its pathogenicity is obtained from its de novo occurrence
and from the phenotypic overlap of individual 15 with
individuals harboring probably disease-causing variants
in POLR2A; this overlap includes symptoms such as
extreme hypotonia with a frog-like positioning of the
legs, developmental delay, strabismus, recurrent respira-
tory tract infections, and wide ventricles, a thin corpus
callosum, and bilateral white-matter loss on brain MRI.
However, arguments against its pathogenicity are that
the variant has been reported three times in gnomAD
and that it is part of a poorly conserved region with no
known functional importance. We stress the importance
of including these unresolved issues when describing
novel disease-causing genes because this aids the subse-
quent resolution of variant pathogenicity whenmore indi-
viduals are described.
In our search for lines of evidence to support pathoge-
nicity, we found an extra line of evidence to support
pathogenicity of the variants in POLR2A in the design of
a desert Z score. While the CADD score,32 which is
usually seen as an estimate of the likelihood of a variant
being pathogenic, did not differentiate between variants re-
ported in gnomAD and the missense variants reported
here, the variants that we report appeared to cluster within
POLR2A in large regions devoid of apparently harmless
variants reported in gnomAD. We calculated the desert
Z score to reflect this property for all variants within
POLR2A. This score confirmed not only that the size of
these regions exceeded the size that would be expected by
chance (the largest region had a Z score of 11.9), but also
confirmed the clustering of individuals’ variants within
these regions. The relevance of this finding was supported
by subsequent structural analyses that unveiled the func-
tional importance of these ‘‘desert regions.’’ We therefore
anticipate, in line with Lelieveld et al. and Havrilla
et al.,45,46 that this property might be helpful to identify
within-gene regions that are relatively intolerant of genetic
variants and are likely to be of functional importance.
The quantification of phenotypic severity unveiled that
individuals harboring heterozygous truncating variants
that are incapable of proper pol II formation presented
with amild phenotype, whereas individuals harboring het-
erozygous missense variants that allow the formation of
pol II exhibited the most severe phenotype. This observa-
tion implies that the presence of a malfunctioning species
of pol II is more detrimental than the reduced availability
of pol II alone.We propose that the aberrant pol II enzymes
are capable of the proper assembly of the pol II machinery
at the transcription start sites, but subsequent elongation
of the nascent RNA occurs at reduced rates and possibly
with an increased error rate, blocking access to and pro-
gression of WT pol II on the same DNA strand. Altogether,
this could greatly influence the dynamics of pol II initia-
tion and release, both of which are essential components
of transcriptional regulation.21 The results reported here
direct further mechanistic studies to investigate this defec-
tive elongation hypothesis.
Malfunctioning pol II has deleterious consequences on
transcription. To date, none of the eleven other pol II sub-
units have been implicated in humandisease. Interestingly,
we noticed some phenotypic overlap between individuals
harboring variants in POLR2A and individuals harboring
variants in subunits of pol III. Mutations in POLR1C
(MIM: 610060, encoding a subunit that is part of both pol
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III and pol I), POLR3A (MIM: 614258), and POLR3B (MIM:
614366) have been described to cause hypomyelinat-
ing leukodystrophy 11 (HLD11, MIM: 616494), 7 (HLD7,
MIM: 607694), and 8 (HLD8, MIM: 614381), respectively.
These three diseases are summarized under the name
POLR3-related leukodystrophy.51 Recently, two individuals
with HLD were reported to harbor mutations in POLR3K,52
thereby expanding the list of potential genetic defects
underlying POLR3-related leukodystrophy. In addition to
hypomyelination on brain imaging, the clinical phenotype
of POLR3-related leukodystrophy is characterized by pro-
gressive cerebellar dysfunction and cognitive dysfunction.
Non-neurological features are abnormal dentition and
hypogonadotropic hypogonadism. Phenotypic features
of POLR3-related leukodystrophy that are also noted
in POLR2A individuals are delayed myelination (5/15),
white-matter loss (6/15), and tooth misalignment (5/15).
However, the cellular functions of the three nuclear
RNA polymerases are different; pol III and pol II are respon-
sible for tRNA and mRNA synthesis, respectively. This can
be reconciled by the proposal that mutations in both pol
II and pol III subunits can affect protein synthesis via
differentmechanisms, and this can result in similar clinical
phenotypes.
In addition to POLR3-related leukodystrophy, POLR1A
has been associated with both acrofacial dysostosis53
(MIM: 616462) and severe neurodegenerative disease with
ataxia, psychomotor retardation, cerebellar and cerebral
atrophy, and leukodystrophy;54 POLR3A is also, in addition
to HLD7, associated with Wiedemann-Rautenstrauch syn-
drome, a neonatal progeroid syndrome55 (MIM: 264090),
and has been discussed as potential cause of hereditary
ataxia and spastic paraparesis,56,57 implying a broader
phenotypic range for POLR3Amutations.
In summary, we here report that heterozygous de novo
variants in POLR2A, which is indispensable for the synthe-
sis of mRNA and several non-coding RNAs as it encodes the
RPB1 subunit of pol II, can result in a neurodevelopmental
syndrome characterized by profound infantile-onset hypo-
tonia and developmental delay. We conclude that the clin-
ical consequences of probably disease-causing variants in
POLR2A are dependent on their effect on pol-II-mediated
transcription because POLR2A variants predicted to result
in loss of RPB1 protein are better tolerated than missense
variants, which we propose can cause a dominant-negative
effect on pol-II-dependent transcription.
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